Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma.

Marianna CarrabottaMaria Antonella LaginestraGiorgio DuranteCaterina MancarellaLorena LanduzziAlessandro ParraFrancesca RuzziLisa ToracchioAlessandra De FeoVeronica GiustiMichela PaselloAlberto RighiPier-Luigi Lollini Emanuela PalmeriniDavide Maria DonatiMaria Cristina ManaraKatia Scotlandi

Published in: Cancer research (2022)

This study identifies altered HMGA2/IGF2BP/IGF2 signaling in CIC-DUX4 sarcomas and provides proof of principle for combination therapy with trabectedin and AKT/mTOR dual inhibitors to specifically combat the disease.

Keyphrases

combination therapy
cell proliferation
pi k akt
signaling pathway
binding protein
genome wide
growth hormone
high grade